Click on Image to Enlarge
PTM uses a Conditioned Target Discovery Platform for focused disease target discovery. The platform can be adopted for multiple disease indications.
The Conditioned Target Discovery Platform is an evolution of the conditioned immunization protocol that generated PTM-001, the first therapeutic candidate of PTM Therapeutics. PTM-001 was derived using inflammatory cytokine (Interferon Gamma) treated colonic epithelial cells as an immunogen. This is the model for more directed target discovery, looking for cellular responsive elements to known stimuli.
Click on Image to Enlarge
For cancer indications, the Conditioned Target Discovery Platform uses a co-culture method, culturing Mesenchymal cells and Tumor cells together. This is designed to capture the cell surface proteome as dictated by the intricate biological cross talk between the affected disease tissues. We feel this will allow for the discovery of more relevant therapeutic targets and targets modified by disease specific post translational modifications.
Click on Image to Enlarge